Omeros Corporation (OMER) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company's remarks, we will conduct a question and answer session. Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today. I'll turn the call over to Jennifer Williams, investor relations for Omeros. Good afternoon, and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. These statements are based on management's beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special notes in the risk factor section regarding forward-looking statements in the company's quarterly report on Form 10-Q, which was filed today with the SEC. and the risk factor section of the company's most recent annual report on Form 10-K for a discussion of these risks and uncertainties. Now, I would like to turn the call over to Dr. Greg Dimopoulos, Chairman and CEO of O'Meara. Thank you, Jennifer, and good afternoon, everyone. I'm joined on today's call by David Borges, our Chief Accounting Officer, Nadia Dock, our Chief Commercial Officer, Andreas Grauer, our Chief Medical Officer, Kathy Melfi, our Chief Regulatory Officer, and Steve Whitaker, our Vice President of Clinical. Today I'll start with an overview of our first quarter financial results and provide updates across our development programs. David will then go through our financials in more detail and will open the call for questions. No...